SIBP-02 + cyclophosphamide + doxorubicin + vincristine + prednisone

**SIBP-02 + cyclophosphamide + doxorubicin + vincristine + prednisone** is an experimental combination regimen likely used for the treatment of neoplastic diseases, particularly hematological malignancies such as lymphoma. SIBP-02 appears to be an investigational agent, though no detailed public information was found on its structure or action. The other agents—cyclophosphamide, doxorubicin, vincristine, and prednisone—comprise the established "CHOP" chemotherapy regimen, which includes an alkylating agent (cyclophosphamide), an anthracycline antibiotic/topoisomerase II inhibitor (doxorubicin), a vinca alkaloid (vincristine), and a corticosteroid (prednisone). These agents act synergistically to inhibit tumor cell proliferation through DNA damage, mitotic arrest, and immunosuppression[2][3].